RadNet (RDNT) Q2 2026 earnings review
Top-Line Records and AI Momentum Mask a Near-Term Earnings Squeeze
RadNet delivered a massive quarter for growth, posting record Q2 revenue of $622.7 million (up 25% YoY) and Adjusted EBITDA of $99.7 million. The company is successfully executing its transition toward high-margin advanced imaging (MRI, CT, PET/CT) and scaling its Digital Health software business, which saw Annual Recurring Revenue (ARR) nearly double YoY to $105.5 million. Management demonstrated high confidence by raising full-year 2026 guidance for the core Imaging segment. However, the aggressive push into AI and software is taking a toll on the bottom line. Heavy investments in Digital Health headcount, combined with one-time acquisition and debt restructuring costs, caused Adjusted EPS to drop to $0.29 from $0.34 a year ago. RadNet is trading short-term profitability for long-term market dominance in radiology AI.
🐂 Bull Case
Digital Health ARR reached $105.5 million, up 97.2% YoY, with 63% now generated from external customers. The transition to a high-margin software-as-a-service model is accelerating rapidly.
High-margin advanced imaging procedures (MRI, CT, PET/CT) grew 21.2% in aggregate and expanded to 29.9% of total volume, proving RadNet's strategy to capture high-acuity diagnostics is working.
🐻 Bear Case
Despite 25% revenue growth, Adjusted EPS dropped. Growth is being funded by heavy spending, leading to severe margin compression in the Digital Health segment.
Net Debt to Adjusted EBITDA sits at 1.8x, up from 0.96x a year ago due to aggressive Q1 M&A. The company absorbed a $3.4M loss from debt restructuring this quarter.
⚖️ Verdict: 🟢
Bullish. The bottom-line hit is by design. RadNet is transparently using its highly profitable core imaging centers to fund a land-grab in radiology AI. The raised guidance and surging ARR justify the short-term earnings pain.
Key Themes
Advanced Imaging Driving Core Profitability
RadNet's deliberate shift away from routine imaging toward complex procedures is accelerating. Advanced imaging (MRI, CT, PET/CT) jumped 238 basis points to 29.9% of total volume. Aggregate advanced procedures surged 21.2% YoY, while same-center volumes grew 9.6%. This favorable mix is the primary reason the Imaging Center segment's Adjusted EBITDA margin ticked up to 16.1%.
Digital Health ARR Hypergrowth
The DeepHealth software division is demonstrating explosive commercial traction. Annual Recurring Revenue (ARR) sequentially increased from $96.9M in Q1 to $105.5M in Q2, an astonishing 97.2% YoY increase. Critically, 63% of this revenue now comes from external hospitals and health systems, proving that RadNet is successfully productizing its internal AI tools for the broader market.
Contradiction: Revenue Boom vs Bottom-Line Bust
While management leads with a 'record quarterly revenue' narrative, the bottom line tells a cautionary tale. Unadjusted Net Income halved to $7.5M from $14.5M a year ago. Even after stripping out one-time items, Adjusted EPS fell from $0.34 to $0.29. This contradiction highlights that RadNet's current 25% top-line growth is highly expensive, funded by massive operational investments, R&D, and debt restructuring.
Digital Health Margins Reversing
The massive ARR growth in Digital Health comes at the steep cost of near-term profitability. Segment Adjusted EBITDA actually reversed, shrinking 27.2% YoY to just $2.5M. Management noted this was driven by aggressive headcount investments in sales, marketing, and implementation teams. While labeled a strategic 'trough year,' investors must monitor execution risk as the segment scales.
DeepHealth Breast Ultrasound AI Cleared
Product innovation continues with the FDA clearance of DeepHealth's breast ultrasound AI solution at the end of July. Management expects to roll this out across all RadNet breast imaging centers by year-end. This is a critical driver for both generating new software revenue and reducing internal radiologist reading times, acting as a dual-engine for margin improvement.
Debt Restructuring in a Tough Macro Environment
RadNet is navigating a high-interest-rate macro environment by actively managing its capital structure. The company executed a debt repricing and add-on transaction in June 2026, which resulted in a $3.4M extinguishment loss in Q2. Despite this short-term hit, the move stabilizes the balance sheet for future M&A. Leverage remains healthy at 1.8x Net Debt to Adjusted EBITDA.
Other KPIs
While advanced imaging is booming (+21.2%), routine imaging (x-ray, ultrasound, mammography) grew a modest 7.9% in aggregate, and just 1.7% on a same-center basis. This lagging segment highlights that RadNet's physical center growth is highly reliant on specialized, high-acuity referrals rather than standard preventative care.
Cash decreased slightly from $767.2M at the end of 2025, primarily due to aggressive Q1 acquisitions (Radiology Regional, Northwest Radiology, Gleamer) and heavy Q2 capital expenditures. However, maintaining over $700M in liquidity provides a massive war chest to continue the 'buy and grow' strategy.
Guidance
Accelerating. Raised from the prior $2.355 - $2,405B range. The midpoint of $2.395B implies robust mid-teens percentage growth compared to FY25, validating management's confidence in continued strong referral volumes and advanced imaging mix.
Accelerating. Raised by $5 million at both ends of the range. This upward revision indicates that the core imaging business is successfully absorbing labor inflation and capturing operating leverage from higher-margin procedures.
Stable. Management reaffirmed this guidance, which implies massive 45-55% growth over FY25. Reaching this target relies heavily on the $37 million in new Total Contract Value signed in the first half of 2026.
Reversing. Reaffirmed guidance showing a deep cash burn for the segment. This cements the narrative that 2026 is an investment trough year to build out the commercial infrastructure for DeepHealth.
Key Questions
Path to Digital Health Profitability
Digital Health ARR has nearly doubled, but Adjusted EBITDA dropped 27%. What are the specific revenue thresholds or timelines required for this segment to demonstrate operating leverage and transition from cash burn to cash generation?
Routine Imaging Stagnation
Same-center routine imaging volumes grew only 1.7%. Is this a deliberate strategy to restrict capacity for low-margin exams in favor of advanced imaging, or a broader signal of softening demand in basic preventative diagnostics?
Debt and Leverage Strategy
Following the June debt repricing and an increase in leverage to 1.8x, what is the maximum Net Debt to EBITDA ratio management is willing to tolerate to fund the M&A pipeline?